Ephrat Levy-Lahad

Prof. Ephrat Levy-Lahad

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RWRobert S. Wildin
Robert S. Wildin
FRFred Ramsdell
Fred Ramsdell
JPJane Peake
Jane Peake
FFFrancesca Faravelli
Francesca Faravelli
JCJean-Laurent Casanova
Jean-Laurent Casanova
MBMary E. Brunkow
Mary E. Brunkow

6 March 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PEPaulina Navon Elkan
Paulina Navon Elkan
SPSarah B. Pierce
Sarah B. Pierce
RSReeval Segel
Reeval Segel
TWTomas Walsh
Tomas Walsh
JBJudith Barash
Judith Barash
ELEphrat Levy-Lahad
Ephrat Levy-Lahad
Polyarteritis nodosa is a systemic necrotizing vasculitis with a pathogenesis that is poorly understood. We identified six families with multiple cases of systemic and cutaneous polyarteritis nodosa, consistent with autosomal recessive inheritance. In most cases, onset of the disease occurred during childhood. We carried out exome sequencing in persons from multiply affected families of Georgian Jewish or German ancestry. We performed targeted sequencing in additional family members and in unrelated affected persons, 3 of Georgian Jewish ancestry and 14 of Turkish ancestry. Mutations were assessed by testing their effect on enzymatic activity in serum specimens from patients, analysis of protein structure, expression in mammalian cells, and biophysical analysis of purified protein. In all the families, vasculitis was caused by recessive mutations in CECR1, the gene encoding adenosine deaminase 2 (ADA2). All the Georgian Jewish patients were homozygous for a mutation encoding a Gly47Arg substitution, the German patients were compound heterozygous for Arg169Gln and Pro251Leu mutations, and one Turkish patient was compound heterozygous for Gly47Val and Trp264Ser mutations. In the endogamous Georgian Jewish population, the Gly47Arg carrier frequency was 0.102, which is consistent with the high prevalence of disease. The other mutations either were found in only one family member or patient or were extremely rare. ADA2 activity was significantly reduced in serum specimens from patients. Expression in human embryonic kidney 293T cells revealed low amounts of mutant secreted protein. Recessive loss-of-function mutations of ADA2, a growth factor that is the major extracellular adenosine deaminase, can cause polyarteritis nodosa vasculopathy with highly varied clinical expression. (Funded by the Shaare Zedek Medical Center and others.)

1 September 2007 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
IGInbal Goshen
Inbal Goshen
TKTirzah Kreisel
Tirzah Kreisel
HOHadile Ounallah-Saad
Hadile Ounallah-Saad
PRPaul Renbaum
Paul Renbaum
YZYael Zalzstein
Yael Zalzstein
RYRaz Yirmiya
Raz Yirmiya

5 September 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
EGEfrat Gabai-Kapara
Efrat Gabai-Kapara
ALAmnon Lahad
Amnon Lahad
BKBella Kaufman
Bella Kaufman
EFEitan Friedman
Eitan Friedman
SSShlomo Segev
Shlomo Segev
ELEphrat Levy-Lahad
Ephrat Levy-Lahad
Significance: Inherited mutations in the tumor suppressor genesBRCA1andBRCA2predispose to very high risks of breast and ovarian cancer. For carriers of these mutations, risk-reducing surgery significantly reduces morbidity and mortality. General population screening forBRCA1andBRCA2mutations in young adult women could be feasible if accurate estimates of cancer risk for mutation carriers could be obtained. We determined that risks of breast and ovarian cancer forBRCA1andBRCA2mutation carriers ascertained from the general population are as high as for mutation carriers ascertained through personal or family history of cancer. General screening ofBRCA1andBRCA2would identify many carriers who are currently not evaluated and could serve as a model for population screening for genetic predisposition to cancer.

12 October 2011 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
GTGidon Toperoff
Gidon Toperoff
DADvir Aran
Dvir Aran
JKJeremy D. Kark
Jeremy D. Kark
MRMichael Rosenberg
Michael Rosenberg
TDTatyana Dubnikov
Tatyana Dubnikov
AHAsaf Hellman
Asaf Hellman
Inter-individual DNA methylation variations were frequently hypothesized to alter individual susceptibility to Type 2 Diabetes Mellitus (T2DM). Sequence-influenced methylations were described in T2DM-associated genomic regions, but evidence for direct, sequence-independent association with disease risk is missing. Here, we explore disease-contributing DNA methylation through a stepwise study design: first, a pool-based, genome-scale screen among 1169 case and control individuals revealed an excess of differentially methylated sites in genomic regions that were previously associated with T2DM through genetic studies. Next, in-depth analyses were performed at selected top-ranking regions. A CpG site in the first intron of the FTO gene showed small (3.35%) but significant (P = 0.000021) hypomethylation of cases relative to controls. The effect was independent of the sequence polymorphism in the region and persists among individuals carrying the sequence-risk alleles. The odds of belonging to the T2DM group increased by 6.1% for every 1% decrease in methylation (OR = 1.061, 95% CI: 1.032–1.090), the odds ratio for decrease of 1 standard deviation of methylation (adjusted to gender) was 1.5856 (95% CI: 1.2824–1.9606) and the sensitivity (area under the curve = 0.638, 95% CI: 0.586–0.690; males = 0.675, females = 0.609) was better than that of the strongest known sequence variant. Furthermore, a prospective study in an independent population cohort revealed significant hypomethylation of young individuals that later progressed to T2DM, relative to the individuals who stayed healthy. Further genomic analysis revealed co-localization with gene enhancers and with binding sites for methylation-sensitive transcriptional regulators. The data showed that low methylation level at the analyzed sites is an early marker of T2DM and suggests a novel mechanism by which early-onset, inter-individual methylation variation at isolated non-promoter genomic sites predisposes to T2DM.

9 January 2007 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ELEphrat Levy-Lahad
Ephrat Levy-Lahad
EFE Friedman
E Friedman
BRCA1 and BRCA2 mutations increase breast and ovarian cancer risks substantially enough to warrant risk reduction surgery, despite variable risk estimates. Underlying this variability are methodological issues, and also complex genetic and nongenetic effects. Although many modifying factors are unidentified, known factors can already be incorporated in individualised risk prediction.